(+)-Vincristine
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Explore 39 assets in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
OHSU Knight Cancer Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03842696CT.gov Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | — | Active Not Recruiting | — | — | — |
NCT03147612CT.gov Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01424982CT.gov Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT00933985CT.gov Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | — | Terminated | — | — | — |
NCT00390793CT.gov Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | — | Completed | — | — | — |
NCT00357305CT.gov Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | — | Completed | — | — | — |
NCT00331513CT.gov Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00275080CT.gov Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | — | Completed | — | — | — |
NCT00278330CT.gov Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00763763CT.gov Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive | — | Completed | — | — | — |
NCT00199186CT.gov Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | OHSU Knight Cancer Institute | P2 | BB · 68 |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Imatinib | The University of Hong Kong | P2 | BB |
| Tacrolimus | University of Michigan Rogel Cancer Center | P2 | BB |
| Nilotinib | The University of Hong Kong | P2 | BB |
| Busulfanum | Fred Hutchinson Cancer Center | P2 | BB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BB |
| Dexasone | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (+)-Vincristine in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-blast-phase-chronic-myelogenous-leukemia-bcr-abl1-positive-52883
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →